NuCana Business Summary

NuCana plc (NCNA) is a clinical-stage biopharmaceutical company that operates on a research-and-development business model, currently generating revenue through strategic licensing, milestone payments, and potential future royalty streams rather than commercial product sales. The company’s primary business segment is oncology, where it leverages its proprietary ProTide technology platform to transform widely prescribed nucleoside analogs into more potent, resistance-overcoming anti-cancer metabolites. Its clinical pipeline is anchored by NUC-7738, targeting PD-1 inhibitor-resistant melanoma, and NUC-3373, focused on advanced colorectal and solid tumors. NuCana competes directly with oncology-focused biotechs such as United Therapeutics, C4 Therapeutics, Gritstone bio, and Syros Pharmaceuticals, positioning itself as a specialized platform-play that seeks to disrupt the standard of care for chemotherapy-resistant cancers through superior intracellular delivery mechanisms. The company was co-founded by CEO Hugh S. Griffith, an industry veteran with a pedigree in oncology commercialization from Bioenvision and Abbott, and Chris Wood. As of February 2026, the leadership team includes newly appointed Chief Operating Officer Theresa Bruce, who brings over 25 years of clinical development experience from Nexus Oncology and Veristat, and Interim CFO Ian Webster, who oversees the firm’s financial strategy and cash runway extending into 2029. The executive suite is further supported by Chief Medical Officer Jeffrey Bloss and Non-Executive Chairman Andrew Kay. NuCana maintains a notable institutional investor base, including the Carlyle Group, Baillie Gifford & Co., and Acadian Asset Management, reflecting sustained interest from major healthcare-focused funds despite the company's micro-cap valuation.